Full-Time
Direct Tax Compliance & Processes
Updated on 9/3/2026
QIAGEN
5,001-10,000 employees
Molecular testing consumables, instruments, software
No salary listed
Hilden, Germany
In Person
Bachelor's
 Accounting (1) |
|---|
Get referred to QIAGEN
See people who can refer or advise you
- A university degree in Business Administration, Economics with a focus on Tax and/or Accounting, Tax Administration (Finanzwirt), or a comparable qualification.
- At least 5 years of relevant professional experience gained within an international advisory firm, such as a Big 4 firm, and/or the tax function of a multinational organization.
- Strong understanding of direct tax compliance, tax accounting, and tax reporting requirements.
- Experience with Microsoft Office applications and tax and enterprise resource planning systems such as DATEV and SAP.
- Professional proficiency in English and German with strong written and verbal communication skills.
- Ability to work independently with a high level of accuracy, diligence, and quality awareness.
- Collaborative approach with stakeholder management and influencing skills.
- Further develop and enhance the Tax Compliance Management System while proactively supporting tax governance, tax quality, and change management initiatives.
- Support annual tax reporting at both legal entity and group level, including the calculation of tax positions and preparation of tax-related disclosures under US GAAP and local GAAP requirements.
- Manage direct tax return and compliance processes in collaboration with external advisors across the DACH region.
- Oversee additional tax compliance obligations within the DACH region and maintain the tax compliance calendar.
- Manage inbound and outbound withholding tax matters, including reporting and filing requirements, while identifying and implementing process improvements.
- Serve as a key business partner for Accounting, Treasury, Legal, Operations, and other internal stakeholders on tax-related matters.
- Support tax audits, tax planning activities, and corporate tax restructuring projects.
QIAGEN provides molecular testing solutions for DNA, RNA, and proteins used by researchers and clinicians in life sciences and diagnostics. It offers an end-to-end portfolio spanning sample technologies, assay technologies, and bioinformatics software to guide workflows from sample to data interpretation. Notable products include QIAseq UPXome RNA Library Kits, the QIAstat Dx Viral Vesicular Panel, and the QIAstat Dx Analyzer, a scalable digital PCR system. Its goal is to help users obtain fast, reliable molecular insights by offering an integrated mix of hardware, reagents, and software that support research and patient care.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
Venlo, Netherlands
Founded
1984
Get referred to QIAGEN
See people who can refer or advise you
Simplify's Take
What believers are saying
- August 2026 Q2 revenue hit $535.0 million, beating estimates and reaffirming 2026 outlook.
- August 2026 FDA clearance expanded QIAstat-Dx Rise into gastrointestinal testing.
- July 2026 Philippines Experience Lab and May 2026 NVIDIA deal broaden commercial reach.
What critics are saying
- May 2026 securities investigations target QIAGEN after QuantiFERON guidance cuts and stock drops.
- Q3 2026 revenue guidance of $538.3 million to $543.7 million trails consensus.
- A failed strategic review would leave QIAGEN exposed to slower QuantiFERON growth and valuation pressure.
What makes QIAGEN unique
- QIAGEN’s 5,200-plus QIAstat-Dx placements create recurring consumables pull-through worldwide.
- QIAcuity’s 3,200-plus placements and 2026 assay expansion deepen workflow lock-in.
- QIAGEN Digital Insights combines 25 years of curation with NVIDIA BioNeMo integration.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Bonus/Commission
Local benefits
Referral Program
Volunteer Day
Hybrid Work Options
Employee Assistance Program
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%QIAGEN welcomes Jonathan M. Pratt as Chief Executive Officer. * August 25, 2026 QIAGEN appointed Jonathan M. Pratt as Chief Executive Officer today. Consequently, Pratt assumes operational leadership starting September 1, 2026. He brings over 25 years of global management experience across life sciences, healthcare, and laboratory systems. Most recently, Pratt guided Filtration Group through its acquisition by Parker-Hannifin Corporation in August 2026. Previously, he managed the Waters Division at Waters Corporation as Senior Vice President. He also led Beckman Coulter Life Sciences as President after serving in executive leadership at Pall Corporation. Furthermore, Pratt's deep experience encompasses analytical instruments, software, consumables, services, and bioprocessing applications. "The Supervisory Board unanimously concluded that Jon Pratt is the right leader for QIAGEN's next phase," said Stephen H. Rusckowski, Chairman of the Supervisory Board of QIAGEN. "Jon combines deep knowledge of our markets with a strong international record of strengthening commercial execution and operational performance. His experience across life sciences and laboratory technologies is directly relevant to QIAGEN's portfolio and customers. Building on our strong foundation, we are confident he will advance our commitment to solid profitable growth. On behalf of the Supervisory Board, I also want to thank Thierry Bernard for his leadership, his many contributions to QIAGEN and his support in ensuring continuity during this transition." "QIAGEN is an iconic and trusted brand in life sciences and molecular diagnostics, built on scientific rigor, quality and technologies that support critical laboratory workflows worldwide," Jon Pratt said. "What attracted me to QIAGEN is the combination of talented teams, a differentiated portfolio and close customer relationships. My first priority will be to listen to QIAGEN teams and customers, learn more about the business and understand where we can sharpen our choices, strengthen execution and create greater impact. I look forward to working with the team to advance our vision of making improvements in life possible." Navigating strategic review and sustained growth. Furthermore, outgoing CEO Thierry Bernard steps down as Managing Director and supports smooth transition operations through late 2026. Meanwhile, QIAGEN reaffirmed its financial guidance for the third quarter and full year 2026. The Supervisory Board continuously evaluates strategic review options with independent advisors to maximize shareholder value relative to standalone growth goals. A seamless changeover of life science executives' leadership helps ensure continuity in global health care markets. There is a need for continual innovation in molecular diagnostics to stay ahead in the competitive market. Good management of lab technology helps scientists operate more effectively in diagnostics. The smooth transition of corporate governance helps in the allocation of capital for profitability. With Pratt at the helm, QIAGEN has laid a solid operational foundation for healthcare globally. For more stories on technology leaders shaping the future of enterprise solutions, visit its CXO Insiders.
Qiagen names new CEO as private equity sale talks advance. * August 25, 2026 * - 9:21 am Qiagen has appointed Jonathan Pratt as CEO, bringing in an executive with recent experience overseeing a multibillion-dollar sale as the European molecular diagnostics company considers a potential takeover by private equity firms, according to a report by Bloomberg. The report cites a company statement as revealing that Pratt, who most recently led Filtration Group, where he helped guide the industrial technology company through its recent $9.25bn cash sale to Parker Hannifin, will succeed Thierry Bernard as CEO on 1 September. His appointment comes as Qiagen moves further into a strategic review that could result in the company being acquired. The business has opened a data room, allowing prospective buyers to examine its operations and financials as part of their due diligence, according to people familiar with the matter. EQT and KKR are among the firms assessing potential bids, with some prospective buyers also considering partnerships with strategic industry players, the people said. Discussions remain ongoing and there is no guarantee that any interested party will ultimately submit an offer. Qiagen's shares were trading 3.4% lower at $42.57 in New York on Monday, valuing the company at about $8.8bn. Earlier reports indicated that some potential bidders had considered offers of at least $50 a share. The company provides molecular testing technologies and services to pharmaceutical companies, research organisations and clinical laboratories. A takeover would rank among Europe's larger healthcare transactions this year and could bring an end to years of speculation over Qiagen's ownership.
QIAGEN has appointed Jonathan M. Pratt as chief executive officer, effective 1 September 2026. Pratt brings over 25 years of leadership experience in life sciences and laboratory technologies. He most recently served as president and CEO of Filtration Group, leading the business through its sale to Parker-Hannifin Corporation in August 2026. He previously held senior positions at Waters Corporation, Beckman Coulter Life Sciences, and Pall Corporation. Pratt will succeed Thierry Bernard, who will step down as CEO and managing director but support the transition through year-end. He will be proposed for shareholder approval as a managing director at an extraordinary general meeting planned for the fourth quarter of 2026. QIAGEN reaffirmed its outlook for the third quarter and full year 2026. The company's strategic review continues.
Qiagen's international operations generated mixed results in the quarter ended June 2026, with total revenue reaching $535.04 million, up 0.3% year-over-year. The Asia Pacific, Japan and Rest of World region contributed $72 million, representing 13.5% of total revenue but falling 2.08% short of the $73.53 million analyst consensus. Europe, Middle East and Africa generated $178 million, accounting for 33.3% of revenue, missing Wall Street projections of $182.07 million by 2.24%. For the current quarter, analysts project total revenue of $541.05 million, a 1.6% year-over-year increase. Asia Pacific, Japan and Rest of World is expected to contribute 14.4%, whilst Europe, Middle East and Africa should account for 35.7% of total revenue.
Qiagen reported second-quarter earnings of $103.4 million, with adjusted earnings per share of 62 cents, surpassing Wall Street expectations of 60 cents. The Netherlands-based diagnostic products maker posted revenue of $535 million, beating analysts' forecasts of $527.9 million. The company's net income translated to 50 cents per share before adjustments for amortisation costs and pretax expenses. Six analysts surveyed by Zacks Investment Research had provided the consensus estimates that Qiagen exceeded in both earnings and revenue metrics.